3.1 Assessment of renal injury
The extent of injury caused by cisplatin treatment was assessed in both
mouse strains by plasma creatinine levels (Figure 1A and 1C )
and histological evaluation by a clinical pathologist (Figure 1B
and 1D ). Plasma creatinine concentrations were 4.3-fold and 5.4-fold
higher in day 4 cisplatin-treated C57BL/6 and FVB/N mice, respectively,
compared to day 4 saline controls (p<0.05). In day 3
cisplatin-treated C57BL/6 and FVB/N mice, plasma creatinine
concentrations were increased 2.3-fold and 2.0-fold compared to saline
controls, although this difference was not statistically significant. In
day 3 cisplatin-treated mice, 3/9 (33%) C57BL/6 mice and 5/8 (62.5%)
FVB/N mice showed signs of histological renal injury (injury score ≥ 1),
whereas on day 4, histological damage was observed in 6/8 (75%) and 5/7
(71.4%) cisplatin-treated C57BL/6 and FVB/N mice, respectively.
Histological injury was not observed at any other timepoint, with the
exception of one C57BL/6 mouse in the day 1 cisplatin group (1/9,
11.1%).